Abstract Bardet-Biedl syndrome (BBS), an emblematic disease in the rapidly evolving Weld of ciliopathies, is characterized by pleiotropic clinical features and extensive genetic heterogeneity. To date, 14 BBS genes have been identiWed, 3 of which have been found mutated only in a single BBS family each (BBS11/TRIM32, BBS13/MKS1 and BBS14/MKS4/NPHP6). Previous reports of systematic mutation detection in large cohorts of BBS families (n > 90) have dealt only with a single gene, or at most small subsets of the known BBS genes. Here we report extensive analysis of a cohort of 174 BBS families for 12/14 genes, leading to the identiWcation of 28 novel mutations. Two pathogenic mutations in a single gene have been found in 117 families, and a single heterozygous mutation in 17 families (of which 8 involve the BBS1 recurrent mutation, M390R). We conWrm that BBS1 and BBS10 are the most frequently mutated genes, followed by BBS12. No mutations have been found in BBS11/TRIM32, the identiWcation of which as a BBS gene only relies on a single missense mutation in a single consanguineous family. While a third variant allele has been observed in a few families, they are in most cases missenses of uncertain pathogenicity, J. Muller and C. Stoetzel contributed equally to this work.
Introduction
Bardet-Biedl syndrome (BBS; OMIM 209900) is a clinically pleiotropic, primarily autosomal recessive disorder whose hallmarks include obesity, progressive early-onset retinal degeneration, polydactyly, hypogenitalism, cognitive impairment and kidney dysplasia. Recent functional investigations of BBS genes and their protein products allowed the characterization of BBS as a ciliopathy, an expanding group of clinically distinct but overlapping disorders caused by defects in proteins involved in the centrosomal/primary cilia organelles (Badano et al. 2006) . Homozygosity mapping in consanguineous BBS families demonstrated a surprisingly high level of non-allelic genetic heterogeneity. Since the identiWcation of the Wrst gene in 2000 (BBS6) (Katsanis et al. 2000; Slavotinek et al. 2000) , mutations have been found, to date, in a total of 12 genes (BBS1-12) Badano et al. 2003; Chiang et al. 2004; Fan et al. 2004; Li et al. 2004; Mykytyn et al. 2001 Mykytyn et al. , 2002 Nishimura et al. 2001 Nishimura et al. , 2005 Stoetzel et al. 2006a Stoetzel et al. , 2007 . In addition, single BBS cases have been described carrying homozygous or compound heterozygous mutations in two genes (MKS1 and CEP290/NPHP6/ MKS4) associated in general to other ciliopathies, and it was proposed that these deWne BBS13 and BBS14 (Leitch et al. 2008) . BBS1 and BBS10 each account for about 20-25% of the mutational load in families of European descent, BBS12 for about 8% of the families whereas each of the other nine genes accounts for ·5% of the cases and some of them were found mutated in only few families (Katsanis 2004; Stoetzel et al. 2006a Stoetzel et al. , 2007 or even, for BBS11, in a single family (Chiang et al. 2006) . Two widespread recurrent mutations resulting from founder eVects have been described: M390R in BBS1 Mykytyn et al. 2002 Mykytyn et al. , 2003 and C91fsX95 in BBS10 (Stoetzel et al. 2006a) . Taken together, the known BBS genes account for about 75% of families, suggesting that mutations in known genes have not yet been detected by current investigations and/or that additional BBS genes remain to be identiWed. A further complication is the Wnding that in rare cases, inheritance departs from classic autosomal recessive inheritance and involves three mutated alleles in two genes deWning oligogenic inheritance (Katsanis 2004; Katsanis et al. 2001) . Such third alleles may also modulate expressivity of the clinical phenotype (Katsanis 2004) . We have previously calculated that given the overall frequency of BBS and the contribution of known genes to the mutation load, one can expect that 1 in 50 patients will carry a third bona Wde mutation in a BBS gene by chance alone, as this is the cumulative carrier frequency of such mutations (Laurier et al. 2006) . The genetic heterogeneity is a burden for identifying mutations as the full sequencing of the 12 BBS coding sequences implies more than 150 amplicons and is time-consuming with routine techniques of diagnostic laboratories.
Herein, we analyzed a cohort of 174 families, found BBS mutations in 134 of them and describe 28 novel mutations. We conWrm the high level of private mutations in this heterogeneous condition and highlight the diYcult task of routine mutation identiWcation in the context of genetic counseling for the families. We discuss the available diagnostic strategies, impact on genetic counseling and some features of our observations, such as the unexpected number of heterozygotes for the recurrent BBS1 M390R mutations for which a second mutation was not found, and the lack of conWrmatory mutation for the implication of the TRIM32/BBS11/LGMD in BBS.
Materials and methods

Patients
Since 2002, DNA samples from 350 BBS families, selected on the classical clinical criteria for the Bardet-Biedl syndrome (Beales et al. 1999) , have been steadily referred to our laboratories for mutation screening. To date, half of the cohort (174 families) has been thoroughly investigated: mutations have been identiWed in 134 families (77%), whereas in 40 families (22%) no mutation was detected and are currently being explored for undetected mutations (deletions, promoter sequencing) and new gene identiWcation. The purpose of this paper is to describe the mutational load of the explored cohort of 134 families. Validation of mutations was performed by sequencing of a control population of 96 DNA. We previously reported mutation analysis for part of this cohort (see Supplementary data 1 for more details) (Hichri et al. 2005; Stoetzel et al. 2006a Stoetzel et al. , b, 2007 .
Initial mutation screening of the BBS1, BBS2, BBS4, BBS6, BBS7 and BBS8 genes Mutation screening of the six BBS genes Wrst identiWed was performed by DHPLC analysis using at least two melting temperatures for each amplicon, followed by direct sequencing of the variant PCR fragments as described by Hichri et al. (2005) , or for some initial work on BBS1, 2, 4 or 6, by SSCP. To detect homozygous mutations, subsequent analysis was performed by SSCP and/or by mixing PCR products for DHPLC. When a BBS gene with a mutation was identiWed, its entire coding sequence, including splice sites, was analyzed by direct sequencing.
DNA sequencing and mutation screening PCR ampliWcation was performed on 50 ng of genomic DNA. Bidirectional sequencing of the puriWed PCR products was performed using the ABI Big Dye Terminator Sequencing kit on an ABI3100 automated capillary sequencer (Applied Biosystems). Detailed protocols are available on request. The long range PCR was carried out according to the manufacturer's protocol (Elongase AmpliWcation System by Invitrogen). Primers are available upon request.
Screening for the M390R BBS1 recurrent mutation Screening for the BBS1 recurrent mutation was performed by a direct digestion PCR-RFLP test according to Hichri et al. (2005) . 
Bioinformatics
For each of the mutated BBS genes in our study, the protein sequences were retrieved from the HomoloGene database (Wheeler et al. 2008) and UniProt (2008) Missing proteins in some organism were predicted when possible on the basis of the available sequences and using TBLASTN and the corresponding genome. The genome sequences were retrieved from generic databases such as NCBI (Wheeler et al. 2008) , UCSC (Karolchik et al. 2008) or ENSEMBL (Flicek et al. 2008) .
Multiple alignments were computed using ClustalW (Thompson et al. 1994 ) and were further manually inspected. The BBS6, BBS10 and BBS12 multiple alignments are a subset of the multiple alignment described initially in (Stoetzel et al. 2007 ). The newly described mutations in this study are positioned according to the protein sequences onto their respective multiple alignment. Sequence conservation of the mutated amino acids residues has been analyzed within metazoans. We Wrst looked if the residue was strictly conserved at the position concerned, or the amino acid properties (i.e., hydrophobic or charged) and then if the mutation observed has been already found during the evolution at this position. The results are available at http://bips.u-strasbg.fr/BBS/BBS_NovelMutations_2009. html.
All missense mutations have been tested for pathogenicity using both SIFT (Ng and HenikoV 2003) and the alignments built for this study as queries, and the PolyPhen web server via batch submission mode (Ramensky et al. 2002) .
Splice sites scoring programs such as SpliceView (Rogozin and Milanesi 1997) or NNSPLICE (Reese et al. 1997) were used to evaluate the eVect of various mutations (e.g., silent, or missense changes and intronic variations) aVecting splice sites. Rescue ESE web server (Yeo et al. 2004 ) was used to predict potential exonic splicing enhancers in polymorphic exonic variants (silent or missense variants).
Results
We describe here the results of systematic mutation screening in BBS1-12 in 174 families. As this work extended over several years, diVerent screening strategies were used, including heteroduplex screening by DHPLC, homozygosity mapping in consanguineous families, and use of a dedicated microarray for assaying previously reported BBS mutations (Asper Ophthalmics). In addition, AVymetrix 6.0 arrays were used to detect genome rearrangement with a potential pathogenic eVect. Together, our work led to the identiWcation of mutations in 134 families (77%) of this cohort. Initial results for six BBS genes on a small subset of families were reported earlier (Hichri et al. 2005) , while an analysis of a larger subset were reported for BBS8, BBS10 and BBS12 (Stoetzel et al. 2006a (Stoetzel et al. , b, 2007 . We have referenced 89 diVerent mutations in 10 of the 12 known BBS genes (for a complete description of all mutations see Supplementary Data 1), including 28 alleles that have not been reported previously. These mutations are the basis of all subsequent analyses.
We excluded from our novel pathogenic mutations list two missense observed in two families: two rare missense most likely to be non-pathogenic found as a third allele, R122Q in BBS3 and S574C in BBS7, respectively, in a single family homozygote for a BBS12 frameshift mutation (T257fsX266) and in a single family compound heterozygote for BBS2 (L168fsX200/C307Y) (see Supplementary Data 1).
Our calculation of the mutation load includes for each BBS gene, the count of families (not taking into account occasional third allele to avoid overestimation of families identiWed) and the number of mutated alleles observed in the families. The two most frequently mutated genes are BBS1 in 44 families (32.6%)/79 alleles (30.6%) including nine families with only one mutation identiWed and BBS10 in 44 families (32.6%)/87 alleles (33.7%) with only one family with one mutation identiWed (Fig. 1) . The third most frequently mutated gene is BBS12 with 14 families (10.4% of the families)/28 alleles (10.9%). Overall, BBS1, BBS10 and BBS12 account for about 75% of the identiWed mutational load in our series (or 58% of the total load including the families with no identiWed mutations), consistent with previous studies Mykytyn et al. 2002; Stoetzel et al. 2006a Stoetzel et al. , 2007 . The other BBS genes contribution to the identiWed mutation load is the following: BBS2 in eight families (5.9%)/14 alleles (5.4%); BBS4 in eight families (5.9%)/14 alleles (5.8%) and once as a third allele; BBS5 in three families (2.2%)/6 alleles (2.3%); BBS6 in Wve families (3.7%)/11 alleles (4.3%) and three missense variants as third alleles; BBS7 for two families (1.5%)/5 alleles (1.9%) and one splice mutation as a third allele; BBS8 in three families (2.2%)/5 alleles (1.9%); BBS9 for four families (3.0%)/8 alleles (3.1%). Except for a single missense variant as a third allele of uncertain pathogenicity (see above), no mutations were found for BBS3 encoding the smallest coding sequence (only 187 aa) of the know BBS genes. No mutation was identiWed for BBS11.
Overall, the 28 novel mutations (Table 1 ) cover 8 BBS genes and are distributed as following: 13 nonsense mutations, 5 deletions, 10 missense mutations and 1 splice mutation. Of them, 16 are found at the homozygous state and 11 at the heterozygous state including 7 as a second allele of a recurrent mutation (BBS1:M390R or BBS10:C91fsX95).
For BBS1, four novel mutations were observed: three as a second allele for the recurrent M390R mutation and one (A107fsX) at the homozygous state. For BBS10, all four mutations were the second allele of the recurrent C91fsX95 mutation. For the other BBS genes, the novel mutations had the following distribution at the homozygote state: three for BBS2, four for BBS4, three for BBS5, one for BBS6 and three for BBS9.
Two recurrent mutations have been reported previously, respectively, M390R for BBS1 and C91fsX95 for BBS10 (Mykytyn et al. 2002; Stoetzel et al. 2006a ). The BBS1 M390R mutation was found at the homozygous state in 18 families and as a compound heterozygote allele in 21 families; overall this mutation represents 73.4% (58/79 alleles) of the BBS1 mutational load, in agreement with previous observations Mykytyn et al. 2002) (Fig. 1) . One intriguing observation is the presence of a heterozygous M390R mutation in eight probands in whom no second mutation was detected by sequencing of all BBS1 coding exons. The C91fsX95 mutation represents 48.3% (42/87 alleles) of the BBS10 mutational load encompassing 29 families: 13 families at the homozygous state and 16 at the heterozygous state. This mutation was observed only once as a single heterozygous allele with no second mutation detected in the gene, in contrast to the observation on the recurrent status of heterozygote BBS1 M390R mutation.
Although the newly identiWed mutations were not observed in a panel of 96 control DNA and are not recorded in the single nucleotide polymorphism database (dbSNP) (Wheeler et al. 2008) , we cannot exclude that some of them are not fully pathogenic or may represent normal rare variants. Splice mutation eVect has been checked and except a BBS7 missense allele (discussed later) none of the other novel missense mutations or novel third allele variants were predicted as aVecting splicing. Therefore, we tested these missense mutations using bioinformatic prediction software such as SIFT (Ng and HenikoV 2003) and PolyPhen (Ramensky et al. 2002) , and further assessing sequence conservation around the variant position among metazoan species of each BBS genes. The results are shown in Table 1 and detailed in Supplementary Data 2. Among the nine prospective mutations tested, seven were clearly predicted as deleterious and 1 mutation (BBS9:I154M) is predicted as benign by PolyPhen (however with a score close to the "possibly damaging" threshold) and deleterious by SIFT (see Supplementary Data 2). Although SIFT and PolyPhen already take the conservation of sequences into account, we further investigated evolutionary conservation of the residues aVected by these mutations in metazoan species, based on their positioning onto their respective multiple sequence alignments (Table 1) . Detailed views of the alignments have been prepared using Jalview (Waterhouse et al. 2009 
) (Supplementary Data 3).
With the exception of BBS6, BBS10 and BBS12, which are only present in vertebrates (Kim et al. 2005; Stoetzel et al. 2007 ), all BBS genes do exist in all metazoan species used in our analysis. Among the nine missense mutations, three aVect positions conserved in vertebrates only (BBS2:C307Y, BBS6:I297T, BBS10:G43D), one in chordates and insects (BBS1:L288R) and Wve across all metazoans (BBS2:L221P as hydrophobic residue, BBS4:N309K, BBS5:R56G, BBS9:I154M as hydrophobic residue and BBS9:V81E as hydrophobic residue). The BBS9 I154M where PolyPhen and SIFT give apparently contradictory prediction is located in a stretch of eight amino acids strictly conserved in vertebrates. One BBS7 (S574C) missense variants was present as a third allele and in a family with 2 BBS2 mutations (L168fsX200/C307Y). Apart from that, Wve other families carried three already known mutations or rare missense variant: one is a compound heterozygote family for BBS1 (M390R; R146X) and carries a third BBS6 allele (T57A) (the position is strictly conserved across metazoan and PolyPhen is describing the variation as "possibly damaging" with a score of 1.825) (Katsanis et al. 2000) ; one family is homozygous for a BBS8 mutation (splice mutation T153T) and carries a third BBS7 mutation (M114V mutation also aVecting splicing) (Stoetzel et al. 2006b ); three families carry two BBS10 mutations and a third missense allele in either BBS4 [BBS10:C91fsX95/C91fsX95 and BBS4:L351R] (strictly conserved except in C. elegans, and PolyPhen describing it as "probably damaging" with a score of 2.018) or BBS6 (BBS10:R34P/C91fsX95 with BBS6:I339V) [not likely pathogenic based on previous segregation data (Slavotinek et al. 2002) , the poor conservation across metazoan and the PolyPhen prediction as "benign" with a score of 0.959], and BBS10:C91fsX95/C195W with BBS6:T237A (Hichri et al. 2005; Stoetzel et al. 2006a ) (not likely pathogenic given the high variability of that position among metazoan and the PolyPhen prediction as "benign" with a score of 0.051).
Discussion
A growing number of inherited disorders show extensive genetic heterogeneity implying diYculties in genotyping patients for diagnosis conWrmation and/or genetic counseling. Leber congenital amaurosis (at least 14 genes involved) (den Hollander et al. 2008) , Usher syndrome (at least 11 genes involved) (Saihan et al. 2009) or BBS are examples of numerous gene identiWcations in the last years and continuous struggle for eYcient genotyping. The extensive genetic heterogeneity of BBS has profound implications for diagnostic and genetic counseling applications. Herein, we present a cohort of 134 fully explored BBS patients carrying mutations in the known genes for BBS and report 28 novel mutations. Genotyping investigations have improved in the last years. Ongoing since 2002, our mutation detection strategy has evolved according to novel gene identiWcations and the availability of new methods of investigation. Overall, this evolution combined chronologically the use of single strand conformation polymorphism (SSCP) or denaturing high-performance liquid chromatography (DHPLC) (Hichri et al. 2005 ), sequencing of known BBS genes (primers available on request), screening for recurrent mutations for BBS1 (M390R screened by restrictive test) and for BBS10 and BBS12 because of a single exon (both screened by direct sequencing). In parallel, analysis of consanguineous families was converted from the initial microsatellite analysis into SNP analysis in the last 3 years. More recently, some families were screened by the arrayed primer extension technology for 161 previously described mutations (Asper Ophthalmics) and screened for some of them for genomic rearrangements with the AVymetrix 6.0. Overall, our study conWrms the major contribution of BBS1, BBS10 and (to a lower degree) BBS12 to the mutation load, as these genes account for three quarters of the detected mutant alleles. The importance of the recurrent mutations accounting herein for at least half of the respective mutations of BBS1 and BBS10 highlights the potential value of a preliminary screening for these mutations. Thus, for eYcient and rapid genotyping, it is rewarding to test in priority BBS1, BBS10 and BBS12.
Furthermore, the 28 novel mutations described herein can be added to the global mutational load of the BBS genes and complement previously designed genotyping arrays. In this series, 256 mutated alleles are described of which 49 are newly described alleles (19.1%) and 136 are found only in a single family (53.1% of the mutational load). A similar Wgure was reported by Harville et al. recently, with 11 novel homozygous mutations out of 20 identiWed in consanguineous families (and none of these mutations have been observed in the present study) (Harville et al. 2009 ). This underlines the "private" (one mutation found only in one family) characteristics of BBS mutations in more then half of the cases disclosing a limit for rapid mutation detection in half of the cases. The nine novel mutations found in compound heterozygotes were detected following preliminary screening for a recurrent mutation in BBS1 or BBS10.
Intriguingly, we have an excess of heterozygote mutations especially for BBS1. This can be explained by either an undetected BBS1 mutation (large deletion, mutation in promoter) or if the M390R is the third allele accompanying mutations in a yet not identiWed gene in these families. Seventeen families are in this situation and eight are heterozygotes for the M390R mutation with no other mutation detected to date.
We carried an AVymetrix SNP 6.0 array study on four of the latter and failed to identify any rearrangement in the vicinity of BBS1 or anywhere else in the genome. These results prompted us to check the sensitivity of this approach in detecting known deletions in BBS patients. In this respect, we performed the analysis on two BBS4 deleted samples: VII.28 (del exon 4-5-6) and II.24 (del exon 7-8). Interestingly, the Wrst could be validated using the AVymetrix array (and further validated by RT-PCR), whereas the second one was not detected due to the lack of oligonucleotide probes on the array within the deleted region (see Fig. 2 ).
Validation of missense mutation can be a delicate task and uncertainty about pathogenicity is a major problem for genetic counseling and in particular for prenatal diagnosis. Sequence conservation studies can be rewarding and may be usefully complemented by functional testing. For one missense mutation at the homozygous state in BBS5, we were able to validate its pathogenicity by way of in vivo complementation analysis (Leitch et al. 2008 ) (see Supplementary Data 4) opening the way for future prenatal diagnosis required for the family. Another revealing case is one missense identiWed in a patient who was homozygous for the BBS4 region using microsatellite analysis. We observed for the Wrst time the previously described rare variant K46R in BBS4 (Mykytyn et al. 2003) at the homozygous state (see Supplementary Data 1), which is predicted as very unlikely to be the pathogenic mutation in this family (see Supplementary Data 1) . Nevertheless, functional studies (N.K., manuscript submitted) by way of in vivo complementation analysis reveal that this variation is indeed a real mutation, pointing out some limitation of bioinformatics analysis and conservation studies. Preliminary SNP study for consanguineous families was extremely useful to detect homozygosity in regions with known BBS genes prompting sequencing of the coding sequence of the gene of interest. Seventeen novel mutations were identiWed using this strategy and would have been missed by the available mutation array. While this manuscript was completed, Harville et al. also reported the value of preliminary homozygosity mapping in identifying target BBS genes for sequencing and diagnosis. This strategy is useful for recessive disease with extensive genetic heterogeneity (Cossee et al. 2009 ).
EYcient BBS genotyping to date is based either on classical mutation detection (RFLP for the recurrent M390R mutation and direct sequencing) or on sequencing chip array designed (Asper Ophthalmics) to detect previously reported mutations. However, this latter method of investigations does not cover novel mutations.
Given the high number of private mutations identiWed in BBS patients, and the small numbers of reported mutations for some BBS genes these arrays are certainly useful but have presently a limited power. Herein, we suggest a strategy that could be applied to eYcient mutations detection in BBS patients (see Fig. 3 ). An initial screening encompassing at least the recurrent mutations of BBS1 and BBS10 and/or the full sequence of BBS10 can detect potentially 30-50% of the BBS patients. This could be complemented by the sequencing of the unique coding exon of BBS12, which would increase the detection power by 8%. The recurrent mutation tests have been described previously (Hichri et al. 2005; Stoetzel et al. 2006a) . If the family is consanguineous (or if the parents are from the same region or population group), we advocate a SNP homozygosity study and sequence the BBS gene (s) found in regions of homozygosity. This strategy has permitted us to detect 80% of mutations in our cohort including novel mutations especially associated to recurrent mutations or at the homozygote state in consanguineous families.
For genetic counseling purposes, the spouse of a conWrmed or putative heterozygote patient for a recurrent BBS1 or BBS10 mutations can beneWt from recurrent mutation screen in order to exclude heterozygosity and reduce risk of recurrence. To date, genetic counseling is performed on the basis of a classical autosomal recessive condition with a 25% risk of recurrence. Prenatal diagnosis by molecular analysis of chorionic villi can be oVered if two pathogenic mutations in one BBS gene are clearly and unambiguously identiWed. If no mutation is identiWed the only way to seek for a recurrence in case of a couple with an aVected child is ultrasound detection of polydactyly and/ or enlarged kidneys.
A number of questions remain to be answered. First, how many BBS patients disclose oligogenic inheritance in BBS genes or related ciliopathy genes? In this respect we are currently extensively screening 288 BBS samples in a high-throughput sequencing project on ciliopathies. Undetectable mutations with classical direct sequencing screen such as deletions or duplication or promoter mutation are currently under investigation using the latter strategy and high-density arrays or quantitative PCR analysis. On the basis of homozygosity mapping in families where no gene has been identiWed yet, it is very likely that the unidentiWed BBS genes each account for a small percentage of families. Exon capture combined to high-throughput sequencing will provide identiWcation of the unknown BBS genes and may Fig. 3 Decision tree for identiWcation of mutation in BBS patients. The initial screening can be achieved by several methods, either by the direct sequencing of recurrent mutations or using the Asper array. The complete BBS10 sequence could be sequenced to ensure a full coverage of this gene. Because accounting for 8% of the BBS patients and the presence of a single coding exon, BBS12 can be added to the pool of initial screened genes. Then if no mutation or no second mutation is found, the established consanguineous or possibly consanguineous families (i.e., patients with parents from the same region or population group) should be analyzed by SNP array to perform homozygosity mapping and identify a possible BBS locus even be used in the future for diagnostic purpose (Ng et al. 2009 ).
